Accessibility Menu
KalVista Pharmaceuticals logo

KalVista Pharmaceuticals

(NASDAQ) KALV

Current Price$16.41
Market Cap$782.96M
Since IPO (2016)+85%
5 Year-49%
1 Year+36%
1 Month+10%

KalVista Pharmaceuticals Financials at a Glance

Market Cap

$782.96M

Revenue (TTM)

$15.12M

Net Income (TTM)

$210.31M

EPS (TTM)

$-4.00

P/E Ratio

-3.87

Dividend

$0.00

Beta (Volatility)

0.68 (Low)

Price

$16.41

Volume

68,420

Open

$15.23

Previous Close

$16.41

Daily Range

$15.14 - $16.63

52-Week Range

$9.23 - $19.00

KALV: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About KalVista Pharmaceuticals

Industry

Biotechnology

Employees

270

CEO

Ben Palleiko, MBA

Headquarters

Cambridge, MA 02142, US

KALV Financials

Key Financial Metrics (TTM)

Gross Margin

-17%

Operating Margin

-13%

Net Income Margin

-14%

Return on Equity

-190%

Return on Capital

-69%

Return on Assets

-62%

Earnings Yield

-25.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$782.96M

Shares Outstanding

50.55M

Volume

68.42K

Short Interest

0.00%

Avg. Volume

975.88K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$188.00M

EBITDA

$173.33M

Operating Cash Flow

$152.91M

Capital Expenditure

$434.00K

Free Cash Flow

$153.34M

Cash & ST Invst.

$187.65M

Total Debt

$6.31M

KalVista Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$13.69M

N/A

Gross Profit

$12.46M

N/A

Gross Margin

91.00%

N/A

Market Cap

$782.96M

N/A

Market Cap/Employee

$5.22M

N/A

Employees

150

N/A

Net Income

$49.48M

-17.1%

EBITDA

$42.20M

+7.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$159.57M

+23.2%

Accounts Receivable

$7.12M

N/A

Inventory

$458.00K

N/A

Long Term Debt

$148.16M

+3069.1%

Short Term Debt

$1.43M

-7.0%

Return on Assets

-61.87%

N/A

Return on Invested Capital

-68.86%

N/A

Free Cash Flow

$32.70M

+17.7%

Operating Cash Flow

$32.68M

+17.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMEROmeros Corporation
$11.12+1.55%
RAPTRAPT Therapeutics, Inc.
$58.01+0.00%
ADCTADC Therapeutics S.A.
$4.04+0.75%
RIGLRigel Pharmaceuticals, Inc.
$26.10+2.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.35+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%
QQQInvesco QQQ Trust
$593.02-0.00%

Questions About KALV

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.